allergic rhinitisallergic conjunctivitisnasal steroidsflutcasone furoatAvamisаллергический риниталлергический конъюнктивитназальные глюкокортикостероидыфлутиказона фуроат«авамис»1.Canonica G.W., Bousquet J., Mullol J., Scadding G.K., Virchow J.C. A survey of the burden of allergic rhinitis in Europe. Allergy. 2007, v. 62, Suppl 85, p. 17-25.2.Schatz M. A survey of the burden of allergic rhinitis in the USA. Allergy. 2007, v. 62, Suppl 85, p. 9-16.3.Walker S., Khan-Wasti S., Fletcher M., Cullinan P., Harris J., Sheikh A. Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case control study. J. Allergy Clin. Immunol. 2007, v. 120 (2), p. 381-387.4.Samantha Walker et al. Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: Case control study J. Allergy Clin. Immunol. 2007, v. 120, p. 381-387.5.Bousquet J., Dahl R., Khaltaev N. Global alliance against chronic respiratory diseases. Allergy. 2007, v. 62 (3), p. 216-223.6.Bousquet J., Khaltaev N. Global surveillance, prevention and control of Chronic Respiratory Diseases. A comprehensive approach. Global Alliance against Chronic Respiratory Diseases. World.7.Asher M.I., Montefort S., Bjorksten B., Lai C.K., Strachan D.P., Weiland S.K. et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006, v. 26, No. 368 (9537), p. 733-743.8.Bousquet J., van Cauwenberge P., Khaltaev N. Allergic rhinitis and its impact on asthma. J. Allergy Clin. Immunol. 2001, v. 108 (5 Suppl.), S. 147-334.9.Shekelle P.G., Woolf S.H., Eccles M., Grimshaw J. Clinical guidelines: developing guidelines. BMJ. 1999, v. 318 (7183), p. 593-614.10.Custovic A., Wijk R.G. The effectiveness of measures to change the indoor environment in the treatment of allergic rhinitis and asthma: ARIA update (in collaboration with GA(2)LEN). Allergy. 2005, v. 60 (9), p. 1112-1115.11.Passalacqua G., Bousquet P.J., Carlsen K.H. et al. ARIA update: I-Systematic review of complementary and alternative medicine for rhinitis and asthma. J. Allergy Clin. Immunol. 2006, v. 117 (5), p. 1054-1062.12.Bonini S., Bonini M., Bousquet J. et al. Rhinitis and asthma in athletes: an ARIA document in collaboration with GA2LEN. Allergy. 2006, v. 61 (6), p. 681-692.13.Bousquet J., van Cauwenberge P., Ait Khaled N. et al. Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GALEN). Allergy. 2006, v. 61 (9), p. 1086-1096.14.Passalacqua G., Durham S.R. Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J. Allergy Clin. Immunol. 2007, v. 119 (4) p. 881-891.15.Cruz A.A., Popov T., Pawankar R. et al. Common characteristics of upper and lower airways in rhinitis and asthma: ARIA update, in collaboration with GA(2)LEN. Allergy. 2007, v. 62, Suppl. v. 84, p. 1-41.16.Bousquet J., Khaltaev N., Cruz A. et al. ARIA Update. Allergy. 2008, v. 63 (suppl.).17.Allergic rhinitis and its impact on asthma guidelines: 2010 Revision. J. Allergy Clin. Immunol. 2010, v. 126, No. 3.18.Аллергический ринит и его влияние на астму (ARIA 2008). Возможности использования в России новой версии документа/Баранов А.А., Хаитов Р.М., Чучалин А.Г.,Nikolai Khaltaev, Jean Bousquet и др. Рос. Аллергол. Журн. 2008, № 5, с. 3-8.19.Guyatt G.H., Oxman A.D., Kunz R. et al. What is «quality of evidence» and why is important to clinicians? BMJ. 2008, v. 336, p. 995-998.20.Brozek J.L. et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines Part 3 of 3. The GRADE approach to developing recommendations Allergy. 2011, v. 66, Issue 5, p. 588-595.